UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 6, 2003
---------------
TRIANGLE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
--------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction File Number) Identification No.)
of incorporation)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
--------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
On January 6, 2003, Triangle Pharmaceuticals, Inc. issued a press
release, a copy of which is attached hereto as Exhibit 99.1, and is
incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits. The following document is incorporated by reference to
this Report:
99.1 Press release dated January 6, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
-----------------------------------------------
(Registrant)
January 7, 2003 /s/ Andrew Finkle
----------------------------- -----------------------------------------------
Date (Signature)
Name: Andrew Finkle
Title: Executive Vice President and General
Counsel